JP2011201781A - 抗アレルギー剤 - Google Patents
抗アレルギー剤 Download PDFInfo
- Publication number
- JP2011201781A JP2011201781A JP2010067639A JP2010067639A JP2011201781A JP 2011201781 A JP2011201781 A JP 2011201781A JP 2010067639 A JP2010067639 A JP 2010067639A JP 2010067639 A JP2010067639 A JP 2010067639A JP 2011201781 A JP2011201781 A JP 2011201781A
- Authority
- JP
- Japan
- Prior art keywords
- polysaccharide
- bifidobacteria
- antiallergic agent
- producing
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000043 antiallergic agent Substances 0.000 title claims abstract description 34
- 150000004676 glycans Chemical class 0.000 claims abstract description 143
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 142
- 239000005017 polysaccharide Substances 0.000 claims abstract description 142
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 85
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 244000005700 microbiome Species 0.000 claims abstract description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 17
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 17
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims abstract description 17
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 16
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229930182830 galactose Natural products 0.000 claims abstract description 16
- 239000008103 glucose Substances 0.000 claims abstract description 16
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 14
- 239000000470 constituent Substances 0.000 claims abstract description 9
- 241001608472 Bifidobacterium longum Species 0.000 claims description 23
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 11
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 206010012442 Dermatitis contact Diseases 0.000 claims description 5
- 208000010247 contact dermatitis Diseases 0.000 claims description 5
- 235000013305 food Nutrition 0.000 abstract description 10
- 239000002537 cosmetic Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 5
- 230000001580 bacterial effect Effects 0.000 abstract description 4
- 230000002411 adverse Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 206010070834 Sensitisation Diseases 0.000 description 26
- 230000008313 sensitization Effects 0.000 description 26
- 238000000034 method Methods 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 229920002444 Exopolysaccharide Polymers 0.000 description 16
- 230000003266 anti-allergic effect Effects 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- HJRJRUMKQCMYDL-UHFFFAOYSA-N 1-chloro-2,4,6-trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(Cl)C([N+]([O-])=O)=C1 HJRJRUMKQCMYDL-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 229960003082 galactose Drugs 0.000 description 12
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 12
- 229960005205 prednisolone Drugs 0.000 description 12
- 108010074328 Interferon-gamma Proteins 0.000 description 11
- 150000001768 cations Chemical class 0.000 description 11
- 239000008055 phosphate buffer solution Substances 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 9
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 102000004388 Interleukin-4 Human genes 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- 210000000624 ear auricle Anatomy 0.000 description 8
- 229940028885 interleukin-4 Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 229940107700 pyruvic acid Drugs 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- -1 aluminum ions Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000017307 interleukin-4 production Effects 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 238000000569 multi-angle light scattering Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 235000010378 sodium ascorbate Nutrition 0.000 description 3
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 3
- 229960005055 sodium ascorbate Drugs 0.000 description 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 239000011345 viscous material Substances 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- OVCJDQPBVXUBBF-UHFFFAOYSA-N 1,5-di-O-acetyl 2,3,4,6-tetra-O-methyl glucitol Natural products COCC(OC(C)=O)C(OC)C(OC)C(OC)COC(C)=O OVCJDQPBVXUBBF-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 241000617482 Kiwa Species 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- ATVQUEJOBOKGCC-GBJTYRQASA-N [(2s,3r,4r,5r)-4,5-diacetyloxy-2,3,6-trimethoxyhexyl] acetate Chemical compound COC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC)[C@@H](OC)COC(C)=O ATVQUEJOBOKGCC-GBJTYRQASA-N 0.000 description 1
- OVCJDQPBVXUBBF-REWJHTLYSA-N [(2s,3r,4r,5r)-5-acetyloxy-2,3,4,6-tetramethoxyhexyl] acetate Chemical compound COC[C@@H](OC(C)=O)[C@@H](OC)[C@H](OC)[C@@H](OC)COC(C)=O OVCJDQPBVXUBBF-REWJHTLYSA-N 0.000 description 1
- NVJZDJXSKJXLCB-LJISPDSOSA-N [(2s,3r,4s,5r)-3,5-diacetyloxy-2,4,6-trimethoxyhexyl] acetate Chemical compound COC[C@@H](OC(C)=O)[C@H](OC)[C@H](OC(C)=O)[C@@H](OC)COC(C)=O NVJZDJXSKJXLCB-LJISPDSOSA-N 0.000 description 1
- UUPZYXOWVJCPJT-JJXSEGSLSA-N [(2s,3r,4s,5r)-4,5,6-triacetyloxy-2,3-dimethoxyhexyl] acetate Chemical compound CC(=O)OC[C@H](OC)[C@@H](OC)[C@@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O UUPZYXOWVJCPJT-JJXSEGSLSA-N 0.000 description 1
- ATVQUEJOBOKGCC-YJNKXOJESA-N [(2s,3r,4s,5r)-4,5-diacetyloxy-2,3,6-trimethoxyhexyl] acetate Chemical compound COC[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H](OC)[C@@H](OC)COC(C)=O ATVQUEJOBOKGCC-YJNKXOJESA-N 0.000 description 1
- OVCJDQPBVXUBBF-DGAVXFQQSA-N [(2s,3r,4s,5r)-5-acetyloxy-2,3,4,6-tetramethoxyhexyl] acetate Chemical compound COC[C@@H](OC(C)=O)[C@H](OC)[C@H](OC)[C@@H](OC)COC(C)=O OVCJDQPBVXUBBF-DGAVXFQQSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FJEKYHHLGZLYAT-FKUIBCNASA-N galp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)[C@@H](C)O)C(C)C)C1=CNC=N1 FJEKYHHLGZLYAT-FKUIBCNASA-N 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003214 pyranose derivatives Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
【解決手段】本発明によれば抗アレルギー剤が提供され、この抗アレルギー剤は、ガラクトース、グルコース、およびラムノースを構成成分に含む多糖、または、ビフィドバクテリウム属に属しかつ該多糖を菌体外に産生する微生物を含む。本発明の抗アレルギー剤は、経口用組成物および外用剤組成物のいずれにも用いられ、食品、医薬品、化粧品などに好適に利用され得る。
【選択図】なし
Description
本発明においては、ガラクトース、グルコース、およびラムノースを構成成分に含む多糖が用いられる。この多糖は、構成糖のモル比が、ガラクトース:グルコース:ラムノース=3〜5:1〜3:1であり得る。この多糖は、例えば、ガラクトース:グルコース:ラムノース=4:2:1の場合、以下の式(I):
(1)多糖の構成成分として、ガラクトース、グルコース、およびラムノースを含む。
(2)ガラクトースとグルコースとラムノースとのモル比は3〜5:1〜3:1である。
(3)多糖中にはピルビン酸が含まれてもよく、その場合の含有率は、10質量%以下であり得る。
(4)分子量は、約5万〜1000万、好ましくは約20万〜250万である(ゲル浸透クロマトグラフィー/多角度レーザー光散乱検出(GPC−MALLS)法)。
(5)多糖は、例えば、ガラクトースとグルコースとラムノースとのモル比が4:2:1である場合、以下の式(I)で示される反復構造を含み得る。
ビフィズス菌産生多糖および菌体外多糖産生ビフィズス菌は、抗アレルギー作用を示す。抗アレルギー作用としては、Th1/Th2バランス改善、Th17調節作用、炎症抑制作用、IgE産生抑制作用、ヒスタミンなどのケミカルメディエーター遊離抑制作用、リンパ球活性化作用などが挙げられるが、これらに限定されるものではない。したがって、本発明によれば、ビフィズス菌産生多糖または菌体外多糖産生ビフィズス菌を抗アレルギー剤として使用し得、そしてビフィズス菌産生多糖または菌体外多糖産生ビフィズス菌を含む抗アレルギー剤が提供される。
ビフィドバクテリウム・ロンガムJBL05株(NITE BP−82)の培養および該微生物が産生する多糖の精製は、特許文献1の記載に従った。より詳細には以下の通りである。
実施例1で調製した精製多糖画分をTOYOPEARL HW65S充填カラムを用いてゲル濾過し、GPC−MALLS法により分子量を調べたところ、約54万であった。
実施例1で調製した精製多糖画分を水に溶解し、終濃度20μg/mlまたは200μg/mlとなるように添加した、ウシ胎児血清および抗生物質(抗生物質−抗真菌剤混合溶液、ナカライテスク)を含むRPMI-1640培地中で、C3H/HeJマウス(8週齢、雄、日本クレア)より調製した脾臓細胞を、5%CO2下で37℃にて72時間培養した。培養上清を回収し、Th1型サイトカインであるインターフェロン−γ(IFN-γ)濃度およびTh2型サイトカインであるインターロイキン−4(IL-4)濃度をELISA法(BIOSOURCE、Invitrogen)で測定した。コントロールとして、同量の水を添加して培養し、同様に上記手順を行った。
実施例1で調製した精製多糖画分をリン酸緩衝液(PBS)に溶解し、これをゾンデを用いて、BALB/cマウス(8週齢、雄、株式会社紀和実験動物研究所)5匹に毎日経口投与した(20mg/kg体重/日)。コントロールとして、PBSのみを5匹に毎日経口投与した。ポジティブコントロールとして、プレドニゾロン(Sigma)を5匹に毎日経口投与した(3mg/kg体重/日)。投与開始後4日目に、右耳介に、アセトン(ナカライテスク)に溶解した0.3%の2,4,6-トリニトロ-1-クロロベンゼン(TNCB)(東京化成工業株式会社)を10μl塗布し(感作)、そして左耳介に、アセトンのみを同量塗布した。さらにTNCB塗布(感作)開始後4日目から1日おきに19日目まで本処置を繰り返した。感作開始後も、上記の経口投与は続けた。感作開始日から、TNCBの塗布ごとに耳介の厚さをノギスで測定した。測定は、毎回同じ条件で、同一試験者が行い、平均値を求めた(各群5匹)。感作開始後20日目に耳介の組織学的観察を行った。組織学的観察については、解剖後、10%中性緩衝ホルマリン(和光純薬工業株式会社)で固定した耳介より切片を作製し、ヘマトキシリン・エオシン(H&E)で染色した(株式会社アプライドメディカルリサーチ委託)後、顕微鏡観察した。
実施例4と同様の方法を用い、ビフィドバクテリウム・ロンガムJBL05株(生菌体)の効果を検討した。
NC/Ngaマウス(7週齢、雄、日本エスエルシー)9匹の右耳介に、アセトン(ナカライテスク)に溶解した0.5%の2,4,6-トリニトロ-1-クロロベンゼン(TNCB)(東京化成工業株式会社)を10μl塗布し(感作)、そして左耳介に、アセトンのみを同量塗布した。さらにTNCB塗布(感作)開始後4日目から1日おきに本処置を2回繰り返した。耳介皮膚厚が均等になるように群分けした(各群3匹)。感作開始後9日目から、3匹に、実施例1で調製した精製多糖画分を水に溶解(1mg/ml)し、耳介表裏に各20μlずつ、毎日塗布した。別の3匹にコントロールとして水を、さらに別の3匹にポジティブコントロールとして水に溶解したプレドニゾロン(25mg/ml)を同様に塗布した。ビフィズス菌産生多糖、水、またはプレドニゾロンを塗布する30分以上前に、2日に1回TNCBを塗布した。感作開始日から、TNCBの塗布ごとに耳介の厚さをノギスで測定した。測定は、毎回同じ条件で、同一試験者が行い、平均値を求めた(各群3匹)。
Claims (14)
- ガラクトース、グルコース、およびラムノースを構成成分に含む多糖を含む、抗アレルギー剤。
- 前記多糖が、ガラクトース、グルコース、およびラムノースを3〜5:1〜3:1のモル比で含む、請求項1に記載の抗アレルギー剤。
- 前記多糖が、ビフィドバクテリウム属に属する微生物から得られる多糖である、請求項1から3のいずれかに記載の抗アレルギー剤。
- 前記ビフィドバクテリウム属に属する微生物が、ビフィドバクテリウム・ロンガムである、請求項4に記載の抗アレルギー剤。
- 前記ビフィドバクテリウム・ロンガムが、ビフィドバクテリウム・ロンガムJBL05株(NITE BP−82)である、請求項5に記載の抗アレルギー剤。
- 微生物を含む抗アレルギー剤であって、
該微生物が、
ビフィドバクテリウム属に属し、かつ、
ガラクトース、グルコース、およびラムノースを構成成分に含む多糖を菌体外に産生する、
抗アレルギー剤。 - 前記多糖が、ガラクトース、グルコース、およびラムノースを3〜5:1〜3:1のモル比で含む、請求項7に記載の抗アレルギー剤。
- 前記微生物が、ビフィドバクテリウム・ロンガムJBL05株(NITE BP−82)である、請求項7から9のいずれかに記載の抗アレルギー剤。
- 請求項1から10のいずれかに記載の抗アレルギー剤を含有する経口用組成物。
- アトピー性皮膚炎あるいは接触性皮膚炎を抑制するための、請求項11に記載の経口用組成物。
- 請求項1から6のいずれかに記載の抗アレルギー剤を含有する外用剤組成物。
- アトピー性皮膚炎あるいは接触性皮膚炎を抑制するための、請求項13に記載の外用剤組成物。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010067639A JP5737646B2 (ja) | 2010-03-24 | 2010-03-24 | 抗アレルギー剤 |
CN201180015091.0A CN102812049B (zh) | 2010-03-24 | 2011-03-22 | 抗过敏剂 |
PCT/JP2011/056733 WO2011118552A1 (ja) | 2010-03-24 | 2011-03-22 | 抗アレルギー剤 |
CA2793085A CA2793085A1 (en) | 2010-03-24 | 2011-03-22 | Anti-allergic agent |
EP11759357.4A EP2551283A4 (en) | 2010-03-24 | 2011-03-22 | ANTIALLERGENIC ACTIVE SUBSTANCE |
AU2011230685A AU2011230685B2 (en) | 2010-03-24 | 2011-03-22 | Anti-allergic agent |
RU2012145123/15A RU2553354C2 (ru) | 2010-03-24 | 2011-03-22 | Противоаллергическое средство |
KR1020127027539A KR20130038845A (ko) | 2010-03-24 | 2011-03-22 | 항알레르기제 |
US13/634,336 US20130005959A1 (en) | 2010-03-24 | 2011-03-22 | Anti-allergic agent |
US14/176,219 US20140154218A1 (en) | 2010-03-24 | 2014-02-10 | Anti-allergic agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010067639A JP5737646B2 (ja) | 2010-03-24 | 2010-03-24 | 抗アレルギー剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011201781A true JP2011201781A (ja) | 2011-10-13 |
JP5737646B2 JP5737646B2 (ja) | 2015-06-17 |
Family
ID=44673104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010067639A Active JP5737646B2 (ja) | 2010-03-24 | 2010-03-24 | 抗アレルギー剤 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20130005959A1 (ja) |
EP (1) | EP2551283A4 (ja) |
JP (1) | JP5737646B2 (ja) |
KR (1) | KR20130038845A (ja) |
AU (1) | AU2011230685B2 (ja) |
CA (1) | CA2793085A1 (ja) |
RU (1) | RU2553354C2 (ja) |
WO (1) | WO2011118552A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014185127A (ja) * | 2013-03-25 | 2014-10-02 | Morishita Jintan Co Ltd | 多糖ナノゲルおよびその製造方法、ならびにそれを用いた創傷治癒剤 |
WO2018225557A1 (ja) * | 2017-06-09 | 2018-12-13 | 旭興産株式会社 | 乳酸菌の菌体外多糖及びその用途 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
ES2658310T3 (es) | 2014-12-23 | 2018-03-09 | 4D Pharma Research Limited | Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación |
SI3193901T1 (en) | 2014-12-23 | 2018-06-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
MD3307288T2 (ro) | 2015-06-15 | 2019-12-31 | 4D Pharma Res Ltd | Compoziții care conțin tulpini bacteriene |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
HUE045754T2 (hu) | 2015-06-15 | 2020-01-28 | 4D Pharma Res Ltd | Blautia stercosis és wexlerae gyulladásos és autoimmun betegségek kezelésében történõ alkalmazásra |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
EP3650033B1 (en) | 2015-06-15 | 2022-02-16 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
TWI797067B (zh) | 2015-11-20 | 2023-04-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
CN114712405A (zh) | 2016-03-04 | 2022-07-08 | 4D制药有限公司 | 包含细菌菌株的组合物 |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
WO2018215758A1 (en) | 2017-05-22 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
PT3638271T (pt) | 2017-06-14 | 2021-01-05 | 4D Pharma Res Ltd | Composições contendo estirpes bacterianas |
CA3066561C (en) | 2017-06-14 | 2022-07-19 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus megasphera and uses thereof |
TWI746955B (zh) * | 2018-04-25 | 2021-11-21 | 日商曾根農場股份有限公司 | 第i型過敏用組成物 |
KR102282246B1 (ko) * | 2020-10-27 | 2021-07-27 | 쿼럼바이오 주식회사 | 갈락토스를 함유하는 아토피 피부염의 예방, 개선, 또는 치료용 조성물 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0476003A (ja) * | 1990-07-18 | 1992-03-10 | Tsumura & Co | 新規な多糖体 |
JPH10194979A (ja) * | 1997-01-07 | 1998-07-28 | Teika Corp | イムノグロブリンe抗体産生抑制剤 |
JP2006273852A (ja) * | 2005-03-03 | 2006-10-12 | Meiji Milk Prod Co Ltd | ビフィズス菌を有効成分とするアレルギー予防および/または治療剤 |
WO2007007562A1 (ja) * | 2005-07-08 | 2007-01-18 | Morishita Jintan Co., Ltd. | ビフィドバクテリウム属の微生物が産生する多糖 |
JP2007290978A (ja) * | 2006-04-21 | 2007-11-08 | Unitika Ltd | 酢酸菌の菌体外水溶性多糖を含む免疫調節組成物 |
WO2007125823A1 (ja) * | 2006-04-26 | 2007-11-08 | Mercian Corporation | 免疫調節機能を有する多糖を主成分とする組成物 |
JP2008534659A (ja) * | 2005-04-04 | 2008-08-28 | ヴィルバック・ソシエテ・アノニム | 局所用組成物およびその使用 |
JP2009067679A (ja) * | 2005-12-27 | 2009-04-02 | Univ Of Tokushima | 抗ヒスタミン作用を有する医薬 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI71169C (fi) | 1981-06-25 | 1986-11-24 | Kelco Biospecialties Ltd | Utfaellning av xantangummi |
FR2513518A1 (fr) * | 1981-09-29 | 1983-04-01 | Tubery Pierre | Polysaccharide extrait du gnidia kraussiana, preparation et usages therapeutiques |
JPS58203913A (ja) | 1982-05-25 | 1983-11-28 | Meiji Milk Prod Co Ltd | 高分子多糖類物質mps−82及びその利用 |
JPS59196099A (ja) | 1983-04-21 | 1984-11-07 | Nisshin Oil Mills Ltd:The | ガム類の回収精製方法 |
GB9104286D0 (en) * | 1991-02-28 | 1991-04-17 | Phytopharm Ltd | Pharmaceutical compositions for the treatment of skin disorders |
JPH0770209A (ja) | 1993-07-02 | 1995-03-14 | Takeda Shokuhin Kogyo Kk | 多糖物質nps、その製造法および用途 |
RU2276157C2 (ru) * | 2000-11-27 | 2006-05-10 | Бомсунд Групо Асесор, С.Л. | Полисахарид с иммуностимулирующей активностью, способ его получения и применение |
FR2842201B1 (fr) * | 2002-06-18 | 2005-01-14 | Probest | Nouvel oligosaccharide, compositions cosmetiques et/ou dermatologiques en contenant et ses applications |
WO2005107788A1 (en) * | 2004-04-27 | 2005-11-17 | Oklahoma Medical Research Foundation | Inhibition of allergic contact dermatitis by n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester |
JP2006001922A (ja) | 2004-05-20 | 2006-01-05 | Mitsukan Group Honsha:Kk | アレルギー抑制組成物 |
TW200700074A (en) * | 2005-03-04 | 2007-01-01 | Calpis Co Ltd | Inducer of t cell apoptosis |
JP2008245576A (ja) | 2007-03-30 | 2008-10-16 | Yotsuba Nyugyo Kk | 免疫調節作用が期待できる乳酸菌及び菌体外多糖類 |
-
2010
- 2010-03-24 JP JP2010067639A patent/JP5737646B2/ja active Active
-
2011
- 2011-03-22 AU AU2011230685A patent/AU2011230685B2/en not_active Ceased
- 2011-03-22 CA CA2793085A patent/CA2793085A1/en not_active Abandoned
- 2011-03-22 WO PCT/JP2011/056733 patent/WO2011118552A1/ja active Application Filing
- 2011-03-22 KR KR1020127027539A patent/KR20130038845A/ko not_active Application Discontinuation
- 2011-03-22 US US13/634,336 patent/US20130005959A1/en not_active Abandoned
- 2011-03-22 RU RU2012145123/15A patent/RU2553354C2/ru not_active IP Right Cessation
- 2011-03-22 EP EP11759357.4A patent/EP2551283A4/en not_active Withdrawn
-
2014
- 2014-02-10 US US14/176,219 patent/US20140154218A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0476003A (ja) * | 1990-07-18 | 1992-03-10 | Tsumura & Co | 新規な多糖体 |
JPH10194979A (ja) * | 1997-01-07 | 1998-07-28 | Teika Corp | イムノグロブリンe抗体産生抑制剤 |
JP2006273852A (ja) * | 2005-03-03 | 2006-10-12 | Meiji Milk Prod Co Ltd | ビフィズス菌を有効成分とするアレルギー予防および/または治療剤 |
JP2008534659A (ja) * | 2005-04-04 | 2008-08-28 | ヴィルバック・ソシエテ・アノニム | 局所用組成物およびその使用 |
WO2007007562A1 (ja) * | 2005-07-08 | 2007-01-18 | Morishita Jintan Co., Ltd. | ビフィドバクテリウム属の微生物が産生する多糖 |
JP2009067679A (ja) * | 2005-12-27 | 2009-04-02 | Univ Of Tokushima | 抗ヒスタミン作用を有する医薬 |
JP2007290978A (ja) * | 2006-04-21 | 2007-11-08 | Unitika Ltd | 酢酸菌の菌体外水溶性多糖を含む免疫調節組成物 |
WO2007125823A1 (ja) * | 2006-04-26 | 2007-11-08 | Mercian Corporation | 免疫調節機能を有する多糖を主成分とする組成物 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014185127A (ja) * | 2013-03-25 | 2014-10-02 | Morishita Jintan Co Ltd | 多糖ナノゲルおよびその製造方法、ならびにそれを用いた創傷治癒剤 |
WO2018225557A1 (ja) * | 2017-06-09 | 2018-12-13 | 旭興産株式会社 | 乳酸菌の菌体外多糖及びその用途 |
Also Published As
Publication number | Publication date |
---|---|
EP2551283A1 (en) | 2013-01-30 |
US20140154218A1 (en) | 2014-06-05 |
CA2793085A1 (en) | 2011-09-29 |
RU2012145123A (ru) | 2014-04-27 |
KR20130038845A (ko) | 2013-04-18 |
EP2551283A4 (en) | 2015-04-22 |
RU2553354C2 (ru) | 2015-06-10 |
AU2011230685B2 (en) | 2014-07-24 |
CN102812049A (zh) | 2012-12-05 |
AU2011230685A1 (en) | 2012-10-18 |
JP5737646B2 (ja) | 2015-06-17 |
WO2011118552A1 (ja) | 2011-09-29 |
US20130005959A1 (en) | 2013-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5737646B2 (ja) | 抗アレルギー剤 | |
Jurášková et al. | Exopolysaccharides produced by lactic acid bacteria: from biosynthesis to health-promoting properties | |
Wang et al. | Characterization and immunomodulatory activity of an exopolysaccharide produced by Lactobacillus plantarum JLK0142 isolated from fermented dairy tofu | |
Maeda et al. | Structural characterization and biological activities of an exopolysaccharide kefiran produced by Lactobacillus kefiranofaciens WT-2BT | |
TWI282279B (en) | A61p 37/04 200601 a i vhtw a61p 17/16 200601 a i vhtw | |
Chen et al. | Influences of different drying methods on the structural characteristics and prebiotic activity of polysaccharides from bamboo shoot (Chimonobambusa quadrangularis) residues | |
EP2722386B1 (en) | Crushed cells and composition thereof | |
TWI689585B (zh) | 新穎乳酸菌株及包含新穎乳酸菌株之免疫賦活劑 | |
Guo et al. | In vitro digestion and fecal fermentation of Siraitia grosvenorii polysaccharide and its impact on human gut microbiota | |
JP4369258B2 (ja) | 免疫賦活剤 | |
JP5192808B2 (ja) | ビフィドバクテリウム属の微生物が産生する多糖 | |
JP2005145885A (ja) | アルギン酸オリゴマーからなる免疫機構賦活剤 | |
WO2019208151A1 (ja) | Iv型アレルギー用組成物 | |
JP7330854B2 (ja) | ビフィズス菌増殖用組成物 | |
Tsirulnichenko et al. | Prebiotic properties of licorice root extracts. | |
CN102812049B (zh) | 抗过敏剂 | |
CN116211886A (zh) | 硫酸软骨素及其盐在靶向调节肠道菌群及代谢物中的应用 | |
JP2014185127A (ja) | 多糖ナノゲルおよびその製造方法、ならびにそれを用いた創傷治癒剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130318 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130318 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20131212 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140513 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140714 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140714 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150312 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150407 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150410 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5737646 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |